Abstract: The present invention relates to an oral thin film comprising a polymer matrix in the form of a solidified foam having voids, wherein the polymer matrix contains at least one active pharmaceutical ingredient, at least one first polymer which comprises a water-soluble polymer and at least one second polymer which comprises a mucoadhesive polymer having a number-average molecular weight of equal to or greater than 100,000 g/mol, a method for producing the oral thin film, and the use of such an oral thin film as a medicament.

Abstract: The present invention relates to a multi-layer thin film comprising at least two layers arranged one on top of the other which each comprise at least one polymer, these at least two layers being connected to one another by at least one stitched seam using at least one thread, and to a method for producing such a thin film and to the use thereof as a medicament.

Abstract: A pharmaceutical or nutraceutical composition with raft-forming properties comprises (a) sodium alginate, (b) colloidal microcrystalline cellulose (c) a bicarbonate, and (d) a carbonate.

Abstract: The present invention provides an ophthalmic composition comprising a combination of mydriatic agent and anti-muscarinic agent along with pharmaceutically acceptable excipients, wherein the pH of the composition is in the range of 3.5 to 8.5. The ophthalmic composition of the present invention has synergistic mydriasis effect to induce pupil dilation (Mydriasis) in ophthalmic surgery for pre-operative preparation.

Abstract: Liquid formulations of GLP-2 analogues that make them suitable for long term storage as liquids and/or that makes them especially suitable for delivery by a drug delivery device are described. Solid compositions comprising acetate salts of glucagon-like peptide 2 (GLP-2) analogues useful for making the liquid formulations are also described. The development of these liquid formulations is based on the finding that acetate present in the formulation that originates from the GLP-2 analogues has an effect on the viscosity of the formulation, that during long term storage at 2-8° C. of GLP-2 analogues, the concentration dependence for covalent oligomer formation is inversely dependent on increasing concentration of the GLP-2 analogue, and that GLP-2 analogues used in the formulations are not compatible with phosphate buffer commonly used in the prior art to reconstituted powdered or lyophilized GLP-2 compositions.

Abstract: Disclosed are methods of preparing PUFA-, lipid-soluble vitamin-, lipid-soluble medicament-encapsulated, or other lipid-soluble molecules micelles that enhance shelf life and prevent oxidation by inducing a Maillard reaction between a reducing sugar and a lipid emulsifying agent having at least one amino group in the presence of a PUPA, lipid-soluble vitamin or lipid-soluble medicament. Method steps include: mixing a reducing sugar, and a PUPA, lipid-soluble vitamin or lipid-soluble medicament, with a lipid emulsifying agent having at least one amino group and a purity of at least 95 wt %, and heating the resulting micelle mixture for sufficient time at a sufficient temperature and under reduced pressure below 1 atm with sufficient moisture so that a Maillard reaction occurs between the lipid amino groups and the reducing carbohydrate to provide a Maillard reaction product coating on the micelles that is effective to prevent oxidation of the PUPA, lipid-soluble vitamin or lipid-soluble medicament.

Abstract: Allogenic, acellular compositions comprising extracellular vesicles derived from pre-primed hematopoietic stem cells and more particularly, pre-primed umbilical cord cells are disclosed. The extracellular vesicles comprise microvesicles, exosomes or a combination thereof. Methods of using such compositions to revitalize cells, tissue and organs, as well as methods of making such compositions are also provided.

Abstract: Various aspects described herein relate to a functionalized nanoscale substrate. The functionalized nanoscale substrate includes a functionalized surface of the substrate that includes a boronated portion.

Abstract: Certain embodiments of the invention provide lipid nanoparticles for delivery nucleic acid therapeutics to the lungs.

Abstract: A multi-functional broad-spectrum antiviral and anti-inflammatory nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a combination of therapeutic agents directed to the particular coronavirus encapsulated in a nanoparticle that is surface coated with a targeting moiety. For CoV-2 infections, an antiviral such as the PPAR-? agonist leriglitazone (LG) and an siRNA targeting a conserved sequence of the virus can be encapsulated within a nanoparticle surface coated with a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.

Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.

Abstract: Compositions and dosage forms that contain volatile lipophilic compounds, and methods of manufacturing such compositions and dosage forms, are described.

Abstract: A hydration formula developed through evidence-based research to keep people hydrated for peak performance. Ingredients used to deliver key components include calcium lactate, dextrose, a branched-chain amino acid, a citric acid, a citrate, stevia, potassium sorbate, sodium benzoate, and water. The synergistic action of the disclosed formulation allows for rapid hydration or rehydration of the human body especially after physical activity and exercise, and in particular after high intensity exercise or activity.

Abstract: Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.

Abstract: A method of treating a psychiatric disorder in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an N-methyl-D-aspartate (NMDA) receptor antagonist and a therapeutically effective amount of a KCNQ channel activator. Pharmaceutical compositions comprising an NMDA receptor antagonist and a KCNQ channel activator are also disclosed.

Abstract: A composition for the treatment of treatment resistant depression may include a serotonin and norepinephrine reuptake inhibitor (SNRI), such as venlafaxine; a tetracyclic antidepressant (TeCA), such as mirtazapine; and a mood stabilizer, such as lithium. A method of treating treatment resistant depression may include administering, to a patient in need, a therapeutically effective dosage of the composition.

Abstract: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.

Abstract: Nutritional compositions contain a mixture of ketogenic ingredients including from 80 to 99% weight % 1,3-butanediol (BDO), preferably R-1,3-butanediol, and from 1 to 20 weight % beta-hydroxybutyric acid (BHB), preferably D-beta-hydroxybutyric acid, or an equivalent molar amount of its conjugate base beta-hydroxybutyrate, salts, monoesters, polyesters, or mixtures thereof. In some embodiments, the nutritional compositions for providing ketosis are prepared for oral administration in a solid form, such as bars, bites, tablets, pills or capsules, in a liquid form, such as smoothies, goos, water, carbonated beverages, soft drinks, fermented beverage suspensions, solutions and emulsions, or in a powder form that can be used to prepare drink mixes or can be added as a supplement to other food or drink products. Methods of providing ketosis in a subject include delivering optimal therapeutic ketosis, with rapidity into and extended duration of blood concentrations of D-BHB of between 1 mM and 2.5 mM.

Abstract: An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression. A pharmaceutical composition for preventing and treating an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, continuous intake of the composition can not only inhibit the progression of the aortic aneurysm but also mediate the regression of the aortic aneurysm, thereby producing the effect of improving vital prognosis.

Abstract: A composition comprising alpha-ketoglutaric acid or a pharmaceutically acceptable salt thereof (AKG), and one or more enzymes selected from a group consisting of a lipase, a protease and an amylase, and medical uses thereof in, neurological and/or neurodegenerative disease, neurological trauma, depression or chronic fatigue syndrome.

Abstract: Methods and uses are disclosed herein. A method of treating a disease or disorder associated with improper protein folding within one or more of a subject's cells may include administering an effective amount of a treatment compound into the subject. The treatment compound includes buthionine sulfoximine. The treatment compound provides improved redox conditions to enhance the unfolded protein response and the degradation of protein aggregation. The buthionine sulfoximine may decrease cellular glutathione to achieve the desired oxidative milieu, but not to the extent where cellular toxicity occurs.

Abstract: Methods, formulations, and applications of increasing intracellular glutathione levels with at least one injectable cell membrane permeable prodrug or derivative of cysteine, glutamylcysteine, glutathione, or a combination thereof, to treat, reduce, or prevent cellular and tissue oxidative damage, to increase levels of amino acids, and to treat numerous disease states and conditions including inborn errors of metabolism, nutritional malabsorption, and aging.

Abstract: A specialized immunonutrition supplement can be administered to a surgical patient to reduce post-operative complications by restraining the expansion of myeloid-derived suppressor cells. The supplement includes one or more of L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides, preferably all four of these compounds. The supplement is administered to the patient at least once per day for a time period extending from a pre-operative day that is three to seven days prior to a bladder surgery of the patient to a post-operative day that is three to seven days after the bladder surgery. The supplement can be administered to treat or prevent post-operative paralytic ileus in a bladder cancer patient; treat or prevent surgery-induced, inflammation-induced or cancer-induced cachexia; reduce the incidence of chronic infections resulting from expansion of myeloid-derived suppressor cells in a patient; and/or reduce mRNA expression of pro-inflammatory cytokines in a patient.

Abstract: A method of improving insulin production in a subject in need thereof comprises administering a nutritional composition comprising lysine, arginine, and beta-hydroxy-beta-methylbutyrate (HMB) to the subject. A method of improving insulin secretion in a subject in need thereof comprises administering a nutritional composition comprising lysine, arginine, and HMB to the subject. A nutritional composition comprises about 0.01 to about 15 wt % HMB, about 0.03 to about 40 wt % lysine, and about 0.02 to about wt % arginine.

Abstract: Oil compositions and compositions thereof that can form nanoemulsions or microemulsions are disclosed. Such compositions and compositions thereof can be useful for antimicrobial properties and be used to treat or prevent microbial infections.

Abstract: The invention described herein relates to a prodrug that is converted into a dopamine agonist. The dopamine prodrug may be combined with one or more dopamine antagonists, dopamine receptor inhibitors, or vesicular monoamine transport inhibitors. A prodrug is a biologically inactive compound that can be metabolized by the body into its active form. For example, a prodrug placed on the ocular surface can undergo hydrolysis during penetration of the ocular surface, resulting in a biologically active drug. A prodrug allows for use of a lower concentration of the drug and protects against undesirable side effects. A prodrug can also help augment drug uptake into the target tissue.

Abstract: The present disclosure relates to a composition for preventing, alleviating or treating an eye disease, which contains (7S)-(+)-cyclopentylcarbarmic acid, 8,8-dimethyl-2-oxo-6,7-dihydro-2H,8H-pyrano[3,2-g]chromen-7-yl-ester as an active ingredient. The (7S)-(+)-cyclopentylcarbarmic acid, 8,8-dimethyl-2-oxo-6,7-dihydro-2H,8H-pyrano[3,2-g]chromen-7-yl-ester of the present disclosure exhibits the effect of remarkably reducing intraocular vascular leakage and, as such, can be advantageously used in a composition for preventing, alleviating or treating an eye disease.

Abstract: The present invention relates to compositions and kits including a chemical uncoupler, such as tyrphostin 9 or precursor or a salt thereof, and compositions including a chemical uncoupler, such as tyrphostin 9 in combination with one or more therapeutic agents, for example, L-carnitine, which are useful, for example, in treating obesity, preventing weight gain, promoting weight loss/slimming, and/or treating or preventing the development of diabetes.

Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.

Abstract: This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.

Abstract: The present disclosure targets West Nile virus, Respiratory Syncytial Virus, Influenza viruses such as Avian influenza, and other disease-causing microbes, including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.

Abstract: The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.

Abstract: Antiviral compounds can be utilized to mitigate viral activity of enveloped viruses in an infected host. In some instances, a virally infected biological cell is contacted with an antiviral to mitigate viral activity in the biological cell. In some instances, a virally infected animal is administered an antiviral to mitigate viral activity in the animal. In some instances, an animal is prophylactically administered an antiviral to mitigate viral activity in the animal. Therapeutics and treatments involving antiviral compounds are also described.

Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.

Abstract: An antitumor drug for use in a method for blocking or inhibiting the growth of neoplastic cells in a target region of a living organism. The method comprises treating the neoplastic cells with said antitumor drug simultaneously with the application of electric current waves to the target region for a predefined period of time while the neoplastic cells are treated with the antitumor drug, the electric current waves having a waveform with a fundamental frequency higher than or equal to 2 MHz.

Abstract: Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRF1 and CRF2) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP(10 kD)] was found to potentiates CRF-intracellular Ca2+ release, demonstrating that CRFBP possesses excitatory roles in addition to the inhibitory role established by the N-terminal fragment of CRFBP [CRFBP(27 kD)]. This interaction was CRF2-specific, as CRF1 responses were not potentiated by CRFBP(10 kD). As there were currently no small molecule ligands available that selectively interact with either CRFBP or CRF2, a cell-based assay was miniaturized, wherein CRFBP(10 kD) was fused as a chimera with CRF2?, that allowed us to a perform a high-throughput screen (HTS) of approximately 350,000 small molecules.

Abstract: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

Abstract: Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.

Abstract: This invention relates to methods for treating pain associated with Parkinson's disease (PD). In particular it relates to the use of opicapone for treating PD-associated pain, especially fluctuation-related pain.

Abstract: The present disclosure relates generally to methods of using modulators of COT (cancer Osaka thyroid) for treating, stabilizing, or lessening the severity or progression of liver disease, in particular, Nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

Abstract: Compositions and methods are described for alleviating, preventing, or treating adverse effects of cholinesterase inhibitors by administering an effective amount of an antioxidant to a subject in need thereof. Composition and methods are described for preventing or treating a brain disease by administering a cholinesterase inhibitor and an antioxidant to a subject in need thereof.

Abstract: The present invention relates to a method for predicting the outcome for a subject suffering from a disease. The invention further relates to a diagnostic kit for the prediction of the outcome. The invention further relates to a use of the expression of CHRM3 mRNA or protein as a marker of the outcome. The invention further relates to a method for treating a subject suffering from a disease or disorder associated with an expression of CHRM3 mRNA or protein and activity of CHRM3 protein.

Abstract: A method and composition for enhancing synthesis of adenosine triphosphate (ATP) in mitochondria of brain cells of a human includes providing the composition including a synergistic compound of choline cation and succinate anion (2-) in a molar ratio of choline:succinate of 2:1 in the form of dicholine succinate (DiSu) in a daily dosage that synergistically increases ATP levels in brain cells. The method and composition are formulated to affect frequency and/or severity of various conditions by regulating ATP levels in brain cells. The method and composition are formulated to reduce rate of decline in the brain under conditions of cerebral hypoxia, e.g., due to aging, injury, illness, and the similar conditions.

Abstract: Provided herein are methods and combination therapies useful for the treatment of non-alcoholic fatty liver diseases (NAFLD). In particular, provided herein are methods and combination therapies for treating NAFLD by administering a combination therapy comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and (b) an SGLT-2 inhibitor, or a pharmaceutically acceptable salt or solvate thereof, and (c) a DPP-4 inhibitor, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising (a) the compound of Formula (I), or a pharmaceutically acceptable salt thereof, and (b) an SGLT-2 inhibitor, or a pharmaceutically acceptable salt or solvate thereof, and (c) a DPP-4 inhibitor, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are methods for the treatment of cystic fibrosis in an individual in need thereof. The methods may include the administration of a CFTR modulator, with or without and one or more CFTR modulator therapy optimizing agent. Further disclosed are methods for treating cystic fibrosis in an individual in need thereof which employ detection of one or more biomarkers which may be used to distinguish CFTR modulator responders and non-responders, which may in turn be used to direct therapy in an individual having cystic fibrosis.

Abstract: The present application generally relates to a method to treat a patient with a bacterial infection caused by Clostridium difficile. Particularly the method compromises the step of administering a therapeutically effective amount of diiodohydroxyquinoline, with or without one or more anti-infective agents, to the patient in need of relief from said infection. Methods of uses and composition matters are within the scope of this disclosure.

Abstract: A synthesis procedure for benzazolo[3,2-a]quinolinium chloride salts and the inclusion of chloro-substituent, amino-substituent, and nitro-substituent resulting in several compounds is provided. The compounds are further used as markers due to their fluorescent properties including in hypoxic environments. Furthermore, anti-cancer screening of two BQS, namely, 7-benzyl-3-aminobenzimidazo[3,2-a]quinolinium chloride (ABQ-48: NSC D-763307) and the corresponding 7-benzyl-3-nitrobenzimidazo[3,2-a]quinolinium chloride (NBQ 48: NSC D-763303) are provided.